Flavopiridol, the first cyclin-dependent kinase inhibitor to enter the clinic: Current status

Expert Opinion on Investigational Drugs

Volumn 9, Issue 12, 2000, Pages 2903-2911

  Kelland, L R ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Cancer; Cyclin dependent kinase; Flavopiridol; Inhibitor

Indexed keywords

ALDEHYDE DEHYDROGENASE; ALDEHYDE DEHYDROGENASE INHIBITOR; ANTINEOPLASTIC AGENT; CISPLATIN; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIN A; CYCLIN B; CYCLIN D; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR; DNA; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ETOPOSIDE; FLAVOPIRIDOL; FLUOROURACIL; GLYCOGEN PHOSPHORYLASE; HL 275; INHIBITOR OF APOPTOSIS PROTEIN; MYC PROTEIN; OXALIPLATIN; PACLITAXEL; PROTEIN C FOS; PROTEIN C JUN; PROTEIN P21; PROTEIN P53; PROTEIN SERINE KINASE; RNA POLYMERASE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; ASTHENIA; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DNA INTERACTION; DRUG GLUCURONIDATION; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; DRUG TARGETING; ENZYME INHIBITION; GASTROINTESTINAL TOXICITY; HEAD AND NECK CANCER; HUMAN; HYPOTENSION; IC 50; KIDNEY CANCER; LEUKEMIA; MAJOR CLINICAL STUDY; MOUSE; NONHODGKIN LYMPHOMA; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PROSTATE CANCER; RAT; STOMACH CANCER;

EID: 0033646291     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.9.12.2903     Document Type: Article

References (49)

1. Discovering novel chemotherapeutic drugs for the third millennium
2. Preclinical and clinical development of cyclin-dependent kinase modulators
3. Flavopiridol (L86 8275; NSC 649890), a new kinase inhibitor for tumor therapy
4. Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275
5. Preclinical antitumor evaluation of cyclin-dependent kinase (cdk) inhibitors
6. Flavopiridol (L86-8275): Selective antitumour activity in vitro and activity in vivo for prostate carcinoma cells
7. Potent inhibition of cdc2 kinase activity by the flavonoid L86-8275
8. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (cdk) 2 and cdk4 in human breast carcinoma cells
9. Inhibition of cdk2, cdk4 and cdk7 by flavopiridol and structural analogs
10. Structural basis for specificity and potency of a flavonoid inhibitor of human cdk2, a cell cycle kinase
11. 1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol
12. Flavopiridol inhibits P-TEFb and blocks HIV-1 replication
13. Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression and has potent antitumor activity in vivo against human leukemia and lymphoma xenografts
14. Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53
15. Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol
16. Flavopiridol mediates cell cycle arrest and apoptosis in esophageal cancer cells
17. Flavopiridol induces cell cycle arrest and p53-independent apoptosis in non-small cell lung cancer cell lines
18. Induction of apoptosis and inhibition of c-erbB-2 in breast cancer cells by flavopiridol
19. Bcl-2 independence of flavopiridol-induced apoptosis
20. Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia
21. Flavopiridol: A cytotoxic flavone that induces cell death in noncycling A549 human lung carcinoma cells
22. Cell cycle-independent induction of apoptosis by the anti-tumor drug flavopiridol in endothelial cells
23. Flavopiridol, a cyclin-dependent kinase inhibitor, prevents spindle inhibitor-induced endoreduplication in human cancer cells
24. Identification of cytosolic aldehyde dehyrogenase 1 from non-small cell lung carcinomas as a flavopiridol-binding protein
25. Flavopiridol inhibits glycogen phosphorylase by binding at the inhibitor site
26. Flavopiridol binds to duplex DNA
27. Characterization of an ovarian carcinoma cell line resistant to cisplatin and flavopiridol
28. Drug resistance to the cyclin-dependent kinase (CDK) inhibitor, flavopiridol
29. Potent interaction of flavopiridol with MRP1
30. Antitumoral activity of flavone of flavone L86-8275
31. Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis
32. Metabolism of the anticancer drug flavopiridol, a new inhibitor of cyclin dependent kinases, in rat liver
33. Flavopiridol metabolism in cancer patients is associated with the occurrence of diarrhea
34. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms
35. Determination of flavopiridol (L86 8275; NSC 649890) in human plasma by reversed-phase liquid chromatography with electrochemical detection
36. Phase I clinical and pharmacokinetic trial of flavopiridol
37. A Phase I trial of 1 hour infusion of flavopiridol (FLA), a novel cyclin-dependent kinase inhibitor, in patients with advanced neoplasms
38. Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: The importance of sequence of administration
39. Sequential dependent enhancement of caspase activation and apoptosis by flavopiridol on paclitaxel-treated human gastric and breast cancer cells
40. Potentiation of apoptosis by flavopiridol in mitomycin-C treated gastric and breast cancer cells
41. Phase I trial of sequential paclitaxel and cisplatin in combination with the cyclin dependent kinase inhibitor flavopiridol (flavo) in patients with advanced solid tumors
42. Phase II trial of flavopiridol in metastatic colorectal cancer: Preliminary results
43. A Phase II trial of flavopiridol in patients with stage IV non-small cell lung cancer
44. The cyclin dependent kinase inhibitor flavopiridol is an active and unexpectedly toxic agent in advanced gastric cancer
45. Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: A University of Chicago Phase II Consortium Study
46. Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists
47. Chemical inhibitors of cyclin-dependent kinases
48. Inhibitors of cyclin-dependent kinases as therapeutic agents for the treatment of cancer
49. Discovery and initial characterization of the paullones, a novel class of small-molecule inhibitors of cyclin-dependent kinases